{"id":7922,"date":"2025-09-18T19:00:09","date_gmt":"2025-09-19T02:00:09","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=press_releases&#038;p=7922"},"modified":"2025-09-18T18:01:36","modified_gmt":"2025-09-19T01:01:36","slug":"rakuten-medical-announces-publication-in-head-neck-of-phase-1b-2-clinical-study-of-asp-1929-photoimmunotherapy-in-combination-with-pembrolizumab","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/","title":{"rendered":"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab"},"content":{"rendered":"<div id=\"pl-7922\"  class=\"panel-layout\" ><div id=\"pg-7922-0\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7922-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7922-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ul>\n<li style=\"text-align: left\"><strong><em>Combination therapy showed promising initial efficacy with a median OS of 25.6 months and a preliminary manageable safety profile in recurrent\/metastatic HNSCC<\/em><\/strong><\/li>\n<li style=\"text-align: left\"><strong><em>Global Phase 3 trial of the combination therapy is underway to further evaluate efficacy and safety as a first-line treatment for recurrent HNSCC<\/em><\/strong><\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7922-1\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7922-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7922-1-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"1\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>San Diego, CA \u2014 <\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox\u2122 platform-based photoimmunotherapy, today announced the publication of results from a Phase 1b\/2 clinical study of ASP-1929 photoimmunotherapy in combination with pembrolizumab in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma (HNSCC) in the peer-reviewed journal <\/span><i><span style=\"font-weight: 400\">Head &amp; Neck<\/span><\/i><span style=\"font-weight: 400\">.<\/span><\/p>\n<p>The article presents updated interim evaluation results (data cut-off: April 30, 2024) from 19 patients enrolled in the HNSCC cohort of the open label ASP-1929-181 trial (ClinicalTrials.gov Identifier: NCT04305795). Findings showed early efficacy signals, particulary overall survival (OS), and tolerability. In addition, exploratory biomarker analyses suggested that ASP-1929 photoimmunotherapy plus pembrolizumab may increase anti-tumor immunity at the targeted lesion.<\/p>\n<p><b>Title:<\/b><span style=\"font-weight: 400\"> Safety and Efficacy Findings From a Phase Ib\/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinoma<\/span><\/p>\n<p><b>DOI:<\/b> <a href=\"https:\/\/doi.org\/10.1002\/hed.70014\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1002\/hed.70014<\/span><\/a><\/p>\n<p><b>Key Findings (data cut-off: April 30, 2024):<\/b><\/p>\n<p><b>Efficacy (N=18*):\u00a0<\/b><\/p>\n<ul>\n<li>Median OS: 25.6 months (95% CI, 14.6\u2013NE)<\/li>\n<li>Objective response rate (ORR): 27.8% (95% CI, 9.7\u201353.5), including 22.2% (95% CI, 6.4\u20136) confirmed complete response (CR)<\/li>\n<li>Disease control rate (DCR): 61.1% (95% CI, 35.7\u201382.7)<\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Median time to response: 1.4 months; most responses observed after 1<sup>st<\/sup> cycle of treatment<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">All CRs exceeding 16 months and ongoing at data cutoff<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\"><small>* 18 out of 19 patients received a minimum of one complete treatment with both pembrolizumab and ASP-1929 photoimmunotherapy.<\/small><\/span><\/p>\n<p><b>Safety (N=19):\u00a0<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">All patients experienced <\/span><span style=\"font-weight: 400\">&gt;<\/span><span style=\"font-weight: 400\"> 1 treatment-emergent adverse event (TEAE)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Most common TEAEs: fatigue (57.9%), oral pain (52.6%), constipation (36.8%)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Serious TEAEs observed in 63.2% of patients, most commonly dysphagia and tongue edema (2 patients 10.5% each)\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">No fatal treatment-related AEs; overall safety profile consistent with prior ASP-1929 photoimmunotherapy and pembrolizumab experiences\u00a0<\/span><\/li>\n<\/ul>\n<p><b>Exploratory Biomarker Analyses:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Tumor biopsies showed an increase in CD8+ T-cell densities and reduction of EGFR expression in treated lesions<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">B-cell proliferation and activation in responders further suggested a modification of the tumor microenvironment toward antitumor immunity<\/span><\/li>\n<\/ul>\n<p>\u201cThese early results are encouraging for patients with recurrent or metastatic head and neck squamous cell carcinoma, a population with very limited treatment options,\u201d said David M. Cognetti, The Herbert Kean, MD Professor and Chair, Department of Otolaryngology \u2013 Head and Neck Surgery at Thomas Jefferson University and lead author of the study. \u201cIn this preliminary evaluation, the combination of ASP-1929 photoimmunotherapy and pembrolizumab showed not only durable responses but also a median overall survival of more than two years, highlighting the potential of this novel approach when standard therapies are no longer viable.\u201d<\/p>\n<p>Based on the results, Rakuten Medical has initiated a global Phase 3 ASP-1929-381 trial (ClinicalTrials.gov Identifier: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06699212\" target=\"_blank\" rel=\"noopener\">NCT06699212<\/a>) to further evaluate ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line therapy for recurrent HNSCC. Currently, over 15 clinical sites across the United States, Taiwan, and Japan are actively recruiting patients, with additional sites expected in these regions. To further accelerate enrollment, the trial will also expand to Eastern Europe, including new sites in Ukraine and Poland. Following completion of the Phase 3 trial, Rakuten Medical will evaluate the potential to submit a Biologics License Application (BLA) for ASP-1929 in the United States as early as 2028.<\/p>\n<p><span style=\"text-decoration: underline\"><b>About ASP-1929-181 Study<br \/>\n<\/b><\/span><span style=\"font-weight: 400\">The ASP-1929-181 study is an open label 1b\/2 trial of ASP-1929 photoimmunotherapy with pembrolizumab in patients with EGFR-expressing advanced solid tumors. The trial included a subprotocol for the <\/span><span style=\"font-weight: 400\">treatment of patients with recurrent locally advanced or metastatic HNSCC, which is the subject of this manuscript.<\/span><\/p>\n<p><span style=\"text-decoration: underline\"><b>About ASP-1929-381 Study<br \/>\n<\/b><\/span><span style=\"font-weight: 400\">The ASP-1929-381 study is a multi-regional, multi-center, randomized, open-label Phase 3 trial, designed to assess the efficacy and safety of ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for locoregional recurrent HNSCC without distant metastases. 412 patients globally will be randomized to either an experimental arm receiving ASP-1929 photoimmunotherapy in combination with pembrolizumab, or a control arm receiving the current pembrolizumab-based standard of care (SOC), where patients may receive pembrolizumab alone or in combination with chemotherapy according to the physician's choice. <\/span><span style=\"font-weight: 400\">The primary endpoint is Overall Survival (OS), with key secondary endpoints including Complete Response Rate (CRR) and Overall Response Rate (ORR).<\/span><\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7922-2\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7922-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7922-2-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"2\" ><div class=\"panel-widget-style panel-widget-style-for-7922-2-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>About Rakuten Medical, Inc.<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox\u2122 platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical\u2019s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries\/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit <\/span><a href=\"http:\/\/www.rakuten-med.com\"><span style=\"font-weight: 400\">www.rakuten-med.com<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>About Alluminox\u2122 platform<br \/>\n<\/b><span style=\"font-weight: 400\">The Alluminox\u2122 platform is Rakuten Medical\u2019s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye\u00ae 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical\u2019s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and\/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical\u2019s Alluminox platform-based photoimmunotherapy is investigational.<\/span><\/p>\n<p><b>About ASP-1929<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical\u2019s first pipeline drug developed on its Alluminox\u2122 platform is ASP-1929, an antibody-dye conjugate comprised of the anti- epidermal growth factor receptor (EGFR) antibody cetuximab and IRDye\u00ae 700DX, a light activatable dye. ASP-1929 binds to EGFR, a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority.<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div id=\"pg-7922-3\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-7922-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7922-3-0-0\" class=\"so-panel widget widget_sow-button panel-first-child panel-last-child\" data-index=\"3\" ><div style=\"padding: 30px 0px 0px 0px;\" class=\"panel-widget-style panel-widget-style-for-7922-3-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-button so-widget-sow-button-flat-6fd36f18507f-7922\"\n\t\t\t\n\t\t><div class=\"ow-button-base ow-button-align-center\"\n>\n\t\t\t<a\n\t\t\t\t\thref=\"https:\/\/rakuten-med.com\/us\/contact\/\"\n\t\t\t\t\tclass=\"rakuten-btn sowb-button ow-icon-placement-left ow-button-hover\" \t>\n\t\t<span>\n\t\t\t\n\t\t\tContact Us\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Combination therapy showed promising initial efficacy with a median OS of 25.6 months and a preliminary manageable safety profile in [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7922","1":"press_releases","2":"type-press_releases","3":"status-publish","5":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"Combination therapy showed promising initial efficacy with a median OS of 25.6 months and a preliminary manageable safety profile in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/09\\\/18\\\/7922\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/09\\\/18\\\/7922\\\/\",\"name\":\"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\\\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"datePublished\":\"2025-09-19T02:00:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/09\\\/18\\\/7922\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/09\\\/18\\\/7922\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/09\\\/18\\\/7922\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\\\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.","og_description":"Combination therapy showed promising initial efficacy with a median OS of 25.6 months and a preliminary manageable safety profile in [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/","og_site_name":"Rakuten Medical - To conquer cancer.","og_image":[{"width":1500,"height":900,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/","name":"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"datePublished":"2025-09-19T02:00:09+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/09\/18\/7922\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical Announces Publication in Head &amp; Neck of Phase 1b\/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/7922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/4"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}